Compare Incyte Corporation (INCY) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Infosys Limited — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Infosys Limited trades at $11.18 (market cap $46.65B). The key difference: Infosys Limited is far larger — about 2× Incyte Corporation's market cap, and Infosys Limited pays a 4.63% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | INFY | |
|---|---|---|
Market Cap | $23.11B | $46.65B |
Sector | Health | Technology |
52-Week High | $118.52 | $20.22 |
52-Week Low | $67.38 | $10.49 |
Enterprise Value | $19.13B | $43.87B |
Dividend Yield | — | 4.63% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
